Cholesterol

In two prospective cohort studies and a meta-analysis of present and past studies, elevated LDL triglycerides were associated with increased risk for atherosclerotic CVD and its components, researchers reported.

Low-dose statin therapy vs. placebo and six over-the-counter supplements marketed for cholesterol health.

Adults partaking in time-restricted eating have greater decreases in body weight, fat mass, fasting blood glucose and other cardiometabolic markers compared with controls, according to findings from a systematic review and meta-analysis.

An all-remote hypertension and hypercholesterolemia management program with more than 10,000 participants was associated with significant decreases in BP and LDL at 6 and 12 months compared with education only, researchers reported.

Levels of cholesterol, triglycerides and other serum components that indicate CVD risk increased for women in Japan who underwent menopause in the past 15 years, according to longitudinal data published in Menopause.

CHICAGO — Olpasiran, a small interfering RNA agent directed to the liver, yielded substantial and sustained reductions in lipoprotein(a) concentrations among patients with established atherosclerotic CVD in the phase 2 OCEAN(a)-DOSE study.

CHICAGO — Daily rosuvastatin lowered LDL, total cholesterol and serum triglycerides significantly more than placebo and six common over-the-counter dietary supplements, with no supplement lowering LDL more than placebo, researchers reported.

CHICAGO — In the PROMINENT trial, pemafibrate lowered triglycerides but did not cut the incidence of CV events compared with placebo in patients with type 2 diabetes and mixed dyslipidemia.

BOSTON — There is strong evidence for a casual association between lipoprotein(a) concentration and CV outcomes across ethnicities, and Lp(a) “should be measured at least once” in all adults to identify high CV risk, according to a speaker.

The U.S. Preventive Services Task Force in August published a statement regarding the initiation of statin therapy for the primary prevention of atherosclerotic CVD.